• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Biosergen

5.20 SEK

+4.00 %

Less than 1K followers

BIOSGN

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+4.00 %
-41.57 %
-85.14 %
-87.00 %
-86.84 %
-88.47 %
-91.38 %
-98.68 %
-98.59 %

Biosergen is active in biotechnology. The company specializes in the research and development of antifungal drugs. The product portfolio includes, for example, an antifungal drug for the treatment of invasive fungal infections in immunosuppressed patients. The company collaborates with research institutes and pharmaceutical companies internationally. Biosergen was founded in 2004 and is headquartered in Solna.

Read more
Market cap
12.21M SEK
Turnover
45.13K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
19.8.
2026

Interim report Q2'26

18.11.
2026

Interim report Q3'26

All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release30.06.2026 klo 18.00

Bulletin from the annual general meeting of Biosergen AB

Biosergen
Regulatory press release26.06.2026 klo 18.45

Biosergen AB: Statement from the Board of Directors of Biosergen regarding the merger with Flerie

Biosergen
Regulatory press release26.06.2026 klo 18.40

Biosergen AB: The Board of Directors of Biosergen has resolved on a rights issue of shares of approximately SEK 40 million in connection with the merger with Flerie

Biosergen

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release26.06.2026 klo 18.35

Flerie and Biosergen have agreed on a merger plan - Flerie's first new investment since its listing on Nasdaq Stockholm

Biosergen
Regulatory press release26.06.2026 klo 18.30

Biosergen AB: Biosergen Publishes 2025 Annual Report

Biosergen
Regulatory press release28.05.2026 klo 09.30

Notice of annual general meeting in Biosergen AB

Biosergen
Press release07.04.2026 klo 15.24

BioStock: Biosergen halts BSG005 development

Biosergen
Regulatory press release04.04.2026 klo 22.00

Biosergen AB: Biosergen Pauses Development of BSG005

Biosergen
Regulatory press release10.02.2026 klo 09.30

Biosergen AB: Biosergen publishes interim report for the fourth quarter 2025

Biosergen
Regulatory press release20.11.2025 klo 09.30

Biosergen AB: Determination of Record Date for Reverse Share Split in Biosergen

Biosergen
Press release19.11.2025 klo 15.54

BioStock: Biosergen comments on continued progress in the third quarter

Biosergen
Regulatory press release19.11.2025 klo 09.30

Biosergen AB: Biosergen publishes interim report for the third quarter 2025

Biosergen
Regulatory press release28.10.2025 klo 09.30

Biosergen AB: Biosergen's Nomination Committee appointed

Biosergen
Press release22.09.2025 klo 14.43

BioStock: ECDC sounds alarm on C. auris – Biosergen eyes role in containment

Biosergen
Press release17.09.2025 klo 13.04

Carlsquare: Mrkt BUZZ, Biosergen: Candidozyma auris on the rise in Europe

Biosergen
Press release02.09.2025 klo 16.40

Carlsquare: Research update Biosergen: Ongoing development going according to plan

Biosergen
Press release21.08.2025 klo 10.52

BioStock: Biosergen’s CEO on the preparations for the next clinical phase

Biosergen
Regulatory press release20.08.2025 klo 09.30

Biosergen AB: Biosergen publishes its interim report for the second quarter 2025

Biosergen
Press release25.07.2025 klo 13.16

BioStock: Biosergen strengthens executive team amid clinical momentum

Biosergen
Regulatory press release24.07.2025 klo 15.12

Biosergen AB: Biosergen Appoints Mark Beveridge as Chief Financial Officer

Biosergen